Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox/DMSO Instillation for OAB
NCT00667095Phase 3Terminated
- Sponsor
- Mayo Clinic
- Start
- Apr 2008
- Primary completion
- Jan 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in overactive bladder (OAB) and Urinary urge incontinence (UUI) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Incontinence Quality of Life Score at 3 months. Started Apr 2008; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
overactive bladder (OAB)Urinary urge incontinence (UUI)
Beyond the preview
Go deeper on NCT00667095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00667095.